Analysts Expect Forty Seven Inc (NASDAQ:FTSV) Will Announce Earnings of -$0.72 Per Share

Wall Street analysts expect Forty Seven Inc (NASDAQ:FTSV) to post earnings per share of ($0.72) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Forty Seven’s earnings, with the lowest EPS estimate coming in at ($0.83) and the highest estimate coming in at ($0.64). Forty Seven posted earnings of ($0.56) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 28.6%. The company is scheduled to announce its next earnings report on Thursday, March 26th.

According to Zacks, analysts expect that Forty Seven will report full year earnings of ($2.53) per share for the current year, with EPS estimates ranging from ($2.60) to ($2.45). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.95) per share, with EPS estimates ranging from ($3.08) to ($2.85). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Forty Seven.

Forty Seven (NASDAQ:FTSV) last released its earnings results on Tuesday, November 12th. The company reported ($0.38) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.38). The company had revenue of $15.68 million for the quarter, compared to analyst estimates of $15.80 million.

FTSV has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of Forty Seven in a research note on Wednesday, November 13th. ValuEngine raised shares of Forty Seven from a “hold” rating to a “buy” rating in a research note on Tuesday, November 26th. Zacks Investment Research cut shares of Forty Seven from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. Oppenheimer lowered their target price on shares of Forty Seven from $35.00 to $20.00 in a research note on Wednesday, August 14th. Finally, Mizuho reissued a “buy” rating and set a $18.00 target price on shares of Forty Seven in a research note on Tuesday, November 12th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $22.75.

In other Forty Seven news, Director Ravindra Majeti sold 15,000 shares of Forty Seven stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.26, for a total value of $153,900.00. Following the transaction, the director now owns 1,221,400 shares in the company, valued at $12,531,564. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 37.40% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in FTSV. Tower Research Capital LLC TRC increased its stake in Forty Seven by 5,976.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 4,132 shares of the company’s stock worth $27,000 after purchasing an additional 4,064 shares in the last quarter. River & Mercantile Asset Management LLP acquired a new stake in Forty Seven during the 2nd quarter worth about $35,000. SG Americas Securities LLC purchased a new stake in Forty Seven during the third quarter valued at about $73,000. Metropolitan Life Insurance Co NY purchased a new stake in Forty Seven during the first quarter valued at about $88,000. Finally, Swiss National Bank acquired a new position in shares of Forty Seven in the second quarter worth about $184,000. 54.31% of the stock is owned by institutional investors and hedge funds.

Forty Seven stock traded up $0.80 during trading hours on Wednesday, hitting $14.07. 334,345 shares of the company traded hands, compared to its average volume of 220,390. The firm has a market cap of $534.37 million, a P/E ratio of -3.75 and a beta of 2.44. The company has a quick ratio of 7.48, a current ratio of 7.48 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $8.85 and its two-hundred day simple moving average is $8.96. Forty Seven has a 1-year low of $5.53 and a 1-year high of $23.83.

Forty Seven Company Profile

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Featured Article: Day Trading – Risk Worth the Reward?

Get a free copy of the Zacks research report on Forty Seven (FTSV)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with's FREE daily email newsletter.